The DOI matches its Crossref record; 157 of the 157 references it cites were found in a registry or an index.
FGF Receptors: Cancer Biology and Therapeutics: CANCER BIOLOGY AND THERAPEUTICS ON FGF RECEPTORS
Abstract
Fibroblast growth factors (FGFs) are involved in a variety of cellular processes, such as stemness, proliferation, anti-apoptosis, drug resistance, and angiogenesis. Here, FGF signaling network, cancer genetics/genomics of FGF receptors (FGFRs), and FGFR-targeted therapeutics will be reviewed. FGF signaling to RAS-MAPK branch and canonical WNT signaling cascade mutually regulate transcription programming. FGF signaling to PI3K-AKT branch and Hedgehog, Notch, TGFβ, and noncanonical WNT signaling cascades regulate epithelial-to-mesenchymal transition (EMT) and invasion. Gene amplification of FGFR1 occurs in lung cancer and estrogen receptor (ER)-positive breast cancer, and that of FGFR2 in diffuse-type gastric cancer and triple-negative breast cancer. Chromosomal translocation of FGFR1 occurs in the 8p11 myeloproliferative syndrome and alveolar rhabdomyosarcoma, as with FGFR3 in multiple myeloma and peripheral T-cell lymphoma. FGFR1 and FGFR3 genes are fused to neighboring TACC1 and TACC3 genes, respectively, due to interstitial deletions in glioblastoma multiforme. Missense mutations of FGFR2 are found in endometrial uterine cancer and melanoma, and similar FGFR3 mutations in invasive bladder tumors, and FGFR4 mutations in rhabdomyosarcoma. Dovitinib, Ki23057, ponatinib, and AZD4547 are orally bioavailable FGFR inhibitors, which have demonstrated striking effects in preclinical model experiments. Dovitinib, ponatinib, and AZD4547 are currently in clinical trial as anticancer drugs. Because there are multiple mechanisms of actions for FGFR inhibitors to overcome drug resistance, FGFR-targeted therapy is a promising strategy for the treatment of refractory cancer. Whole exome/transcriptome sequencing will be introduced to the clinical laboratory as the companion diagnostic platform facilitating patient selection for FGFR-targeted therapeutics in the era of personalized medicine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Liang, Z., Wu, H., Reddy, S., Zhu, A., Wang, S., Blevins, D. P., Yoon, Y., Zhang, Y., & Shim, H. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.09.007 · Cited by 126
RetractedExpression of DNMT1 and DNMT3a Are Regulated by GLI1 in Human Pancreatic Cancer
He, S., Wang, F., Yang, L., Guo, C., Wan, R., Ke, A., Xu, L., Hu, G., Xu, X., Shen, J., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0027684 · Cited by 88
RetractedThe protein kinase complement of the human genome
Manning, G., Whyte, D. B., Martinez, R., Hunter, T., & Sudarsanam, S. (2002) · Science · doi:10.1126/science.1075762 · Cited by 8,145
Epithelial–mesenchymal transitions in tumour progression
Thiery, J. P. (2002) · Nature Reviews Cancer · doi:10.1038/nrc822 · Cited by 6,628
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
Kwak, E. L., Bang, Y.-J., Camidge, D. R., Shaw, A. T., Solomon, B., Maki, R. G., Ou, S.-H. I., Dezube, B. J., Jänne, P. A., Costa, D. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1006448 · Cited by 4,446
Fibroblast growth factor signalling: from development to cancer
Turner, N., & Grose, R. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2780 · Cited by 2,693
Targeting cancer with small molecule kinase inhibitors
Zhang, J., Yang, P. L., & Gray, N. S. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2559 · Cited by 2,576
MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts
Thum, T., Gross, C., Fiedler, J., Fischer, T., Kissler, S., Bussen, M., Galuppo, P., Just, S., Rottbauer, W., Frantz, S., et al. (2008) · Nature · doi:10.1038/nature07511 · Cited by 2,349
Genome-wide association study identifies novel breast cancer susceptibility loci
Easton, D. F., Pooley, K. A., Dunning, A. M., Pharoah, P. D. P., Thompson, D., Ballinger, D. G., Struewing, J. P., Morrison, J., Field, H., Luben, R., et al. (2007) · Nature · doi:10.1038/nature05887 · Cited by 2,319
EGFR Antagonists in Cancer Treatment
Ciardiello, F., & Tortora, G. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0707704 · Cited by 2,058
The FGF family: biology, pathophysiology and therapy
Beenken, A., & Mohammadi, M. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2792 · Cited by 1,945
Cellular signaling by fibroblast growth factor receptors
Eswarakumar, V. P., Lax, I., & Schlessinger, J. (2005) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2005.01.001 · Cited by 1,929
Inhibition of Adipogenesis by Wnt Signaling
Ross, S. E., Hemati, N., Longo, K. A., Bennett, C. N., Lucas, P. C., Erickson, R. L., & MacDougald, O. A. (2000) · Science · doi:10.1126/science.289.5481.950 · Cited by 1,874
Molecular requirements for epithelial–mesenchymal transition during tumor progression
Huber, M. A., Kraut, N., & Beug, H. (2005) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2005.08.001 · Cited by 1,821
VEGF-targeted therapy: mechanisms of anti-tumour activity
Ellis, L. M., & Hicklin, D. J. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2403 · Cited by 1,673
Zhou, B. P., Deng, J., Xia, W., Xu, J., Li, Y. M., Gunduz, M., & Hung, M.-C. (2004) · Nature Cell Biology · doi:10.1038/ncb1173 · Cited by 1,581
TGF-β and epithelial-to-mesenchymal transitions
Zavadil, J., & Böttinger, E. P. (2005) · Oncogene · doi:10.1038/sj.onc.1208927 · Cited by 1,578
Structural diversity of G protein-coupled receptors and significance for drug discovery
Lagerström, M. C., & Schiöth, H. B. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2518 · Cited by 1,492
Tyrosine Kinases as Targets for Cancer Therapy
Krause, D. S., & Van Etten, R. A. (2005) · New England Journal of Medicine · doi:10.1056/nejmra044389 · Cited by 1,387
O'Hare, T., Shakespeare, W. C., Zhu, X., Eide, C. A., Rivera, V. M., Wang, F., Adrian, L. T., Zhou, T., Huang, W.-S., Xu, Q., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.09.028 · Cited by 1,259
BIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy
Hilberg, F., Roth, G. J., Krssak, M., Kautschitsch, S., Sommergruber, W., Tontsch-Grunt, U., Garin-Chesa, P., Bader, G., Zoephel, A., Quant, J., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6307 · Cited by 1,056
Apert syndrome results from localized mutations of FGFR2 and is allelic with Crouzon syndrome
Wilkie, A. O. M., Slaney, S. F., Oldridge, M., Poole, M. D., Ashworth, G. J., Hockley, A. D., Hayward, R. D., David, D. J., Pulleyn, L. J., Rutland, P., et al. (1995) · Nature Genetics · doi:10.1038/ng0295-165 · Cited by 935
The biology of vascular endothelial growth factors
TAMMELA, T., ENHOLM, B., ALITALO, K., & PAAVONEN, K. (2005) · Cardiovascular Research · doi:10.1016/j.cardiores.2004.12.002 · Cited by 838
Weiss, J., Sos, M. L., Seidel, D., Peifer, M., Zander, T., Heuckmann, J. M., Ullrich, R. T., Menon, R., Maier, S., Soltermann, A., et al. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3001451 · Cited by 821
WNT Signaling Pathway and Stem Cell Signaling Network
Katoh, M., & Katoh, M. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2316 · Cited by 796
Self-citationTransforming Fusions of FGFR and TACC Genes in Human Glioblastoma
Singh, D., Chan, J. M., Zoppoli, P., Niola, F., Sullivan, R., Castano, A., Liu, E. M., Reichel, J., Porrati, P., Pellegatta, S., et al. (2012) · Science · doi:10.1126/science.1220834 · Cited by 789
Mutations in the fibroblast growth factor receptor 2 gene cause Crouzon syndrome
Reardon, W., Winter, R. M., Rutland, P., Pulleyn, L. J., Jones, B. M., & Malcolm, S. (1994) · Nature Genetics · doi:10.1038/ng0994-98 · Cited by 758
Mining the Wnt pathway for cancer therapeutics
Barker, N., & Clevers, H. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2154 · Cited by 743
Mechanisms of Disease: oncogene addiction—a rationale for molecular targeting in cancer therapy
Weinstein, I. B., & Joe, A. K. (2006) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0558 · Cited by 705
Balancing cell adhesion and Wnt signaling, the key role of β-catenin
Brembeck, F. H., Rosário, M., & Birchmeier, W. (2006) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2005.12.007 · Cited by 668
Mechanisms underlying differential responses to FGF signaling
Dailey, L., Ambrosetti, D., Mansukhani, A., & Basilico, C. (2005) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2005.01.007 · Cited by 649
Deng, N., Goh, L. K., Wang, H., Das, K., Tao, J., Tan, I. B., Zhang, S., Lee, M., Wu, J., Lim, K. H., et al. (2012) · Gut · doi:10.1136/gutjnl-2011-301839 · Cited by 645
Zang, Z. J., Cutcutache, I., Poon, S. L., Zhang, S. L., McPherson, J. R., Tao, J., Rajasegaran, V., Heng, H. L., Deng, N., Gan, A., et al. (2012) · Nature Genetics · doi:10.1038/ng.2246 · Cited by 616
Mode of proviral activation of a putative mammary oncogene (int-1) on mouse chromosome 15
Nusse, R., van Ooyen, A., Cox, D., Fung, Y. K. T., & Varmus, H. (1984) · Nature · doi:10.1038/307131a0 · Cited by 612
Matsui, J., Yamamoto, Y., Funahashi, Y., Tsuruoka, A., Watanabe, T., Wakabayashi, T., Uenaka, T., & Asada, M. (2008) · International Journal of Cancer · doi:10.1002/ijc.23131 · Cited by 551
Katoh, Y., & Katoh, M. (2009) · Current Molecular Medicine · doi:10.2174/156652409789105570 · Cited by 525
Self-citationGavine, P. R., Mooney, L., Kilgour, E., Thomas, A. P., Al-Kadhimi, K., Beck, S., Rooney, C., Coleman, T., Baker, D., Mellor, M. J., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3034 · Cited by 501
RNA sequencing of pancreatic circulating tumour cells implicates WNT signalling in metastasis
Yu, M., Ting, D. T., Stott, S. L., Wittner, B. S., Ozsolak, F., Paul, S., Ciciliano, J. C., Smas, M. E., Winokur, D., Gilman, A. J., et al. (2012) · Nature · doi:10.1038/nature11217 · Cited by 484
RET tyrosine kinase signaling in development and cancer
Arighi, E., Borrello, M. G., & Sariola, H. (2005) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2005.05.010 · Cited by 468
Jabs, E. W., Li, X., Scott, A. F., Meyers, G., Chen, W., Eccles, M., Mao, J.-I., Charnas, L. R., Jackson, C. E., & Jaye, M. (1994) · Nature Genetics · doi:10.1038/ng1194-275 · Cited by 468
Identical mutations in the FGFR2 gene cause both Pfeiffer and Crouzon syndrome phenotypes
Rutland, P., Pulleyn, L. J., Reardon, W., Baraitser, M., Hayward, R., Jones, B., Malcolm, S., Winter, R. M., Oldridge, M., Slaney, S. F., et al. (1995) · Nature Genetics · doi:10.1038/ng0295-173 · Cited by 451
Wang, G., van der Walt, J. M., Mayhew, G., Li, Y.-J., Züchner, S., Scott, W. K., Martin, E. R., & Vance, J. M. (2008) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2007.09.021 · Cited by 440
Turner, N., Lambros, M. B., Horlings, H. M., Pearson, A., Sharpe, R., Natrajan, R., Geyer, F. C., van Kouwenhove, M., Kreike, B., Mackay, A., et al. (2010) · Oncogene · doi:10.1038/onc.2009.489 · Cited by 416
Fibroblast growth factor signaling in tumorigenesis
Grose, R., & Dickson, C. (2005) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2005.01.003 · Cited by 404
Cancer genetics and genomics of human FOX family genes
Katoh, M., Igarashi, M., Fukuda, H., Nakagama, H., & Katoh, M. (2013) · Cancer Letters · doi:10.1016/j.canlet.2012.09.017 · Cited by 401
Self-citationA Wnt Survival Guide: From Flies to Human Disease
Chien, A. J., Conrad, W. H., & Moon, R. T. (2009) · Journal of Investigative Dermatology · doi:10.1038/jid.2008.445 · Cited by 376
Dissanayake, S. K., Wade, M., Johnson, C. E., O'Connell, M. P., Leotlela, P. D., French, A. D., Shah, K. V., Hewitt, K. J., Rosenthal, D. T., Indig, F. E., et al. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m700075200 · Cited by 374
The Role of Fibroblast Growth Factors in Tumor Growth
Korc, M., & Friesel, R. (2009) · Current Cancer Drug Targets · doi:10.2174/156800909789057006 · Cited by 355
Dickson, C., Smith, R., Brookes, S., & Peters, G. (1984) · Cell · doi:10.1016/0092-8674(84)90383-0 · Cited by 347
Drug-sensitive FGFR2 mutations in endometrial carcinoma
Dutt, A., Salvesen, H. B., Chen, T.-H., Ramos, A. H., Onofrio, R. C., Hatton, C., Nicoletti, R., Winckler, W., Grewal, R., Hanna, M., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0803379105 · Cited by 345
Wang, Z., Li, Y., Kong, D., & H. Sarkar, F. (2010) · Current Drug Targets · doi:10.2174/138945010791170860 · Cited by 341
Hernández, S., López-Knowles, E., Lloreta, J., Kogevinas, M., Amorós, A., Tardón, A., Carrato, A., Serra, C., Malats, N., & Real, F. X. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.1771 · Cited by 334
Zlobec, I., & Lugli, A. (2010) · Oncotarget · doi:10.18632/oncotarget.199 · Cited by 331
VI, J. G. T., Cheuk, A. T., Tsang, P. S., Chung, J.-Y., Song, Y. K., Desai, K., Yu, Y., Chen, Q.-R., Shah, K., Youngblood, V., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci39703 · Cited by 321
Gozgit, J. M., Wong, M. J., Moran, L., Wardwell, S., Mohemmad, Q. K., Narasimhan, N. I., Shakespeare, W. C., Wang, F., Clackson, T., & Rivera, V. M. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0450 · Cited by 320
Fukuda, T., Chen, L., Endo, T., Tang, L., Lu, D., Castro, J. E., Widhopf, G. F., Rassenti, L. Z., Cantwell, M. J., Prussak, C. E., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0712148105 · Cited by 312
The expanding world of small RNAs
Großhans, H., & Filipowicz, W. (2008) · Nature · doi:10.1038/451414a · Cited by 305
Chamorro, M. N., Schwartz, D. R., Vonica, A., Brivanlou, A. H., Cho, K. R., & Varmus, H. E. (2005) · The EMBO Journal · doi:10.1038/sj.emboj.7600460 · Cited by 298
Trudel, S., Li, Z. H., Wei, E., Wiesmann, M., Chang, H., Chen, C., Reece, D., Heise, C., & Stewart, A. K. (2005) · Blood · doi:10.1182/blood-2004-10-3913 · Cited by 289
Beyond VEGF: Inhibition of the Fibroblast Growth Factor Pathway and Antiangiogenesis
Lieu, C., Heymach, J., Overman, M., Tran, H., & Kopetz, S. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0659 · Cited by 286
Epithelial-mesenchymal transition in gastric cancer.
Huang, L., Wu, R., & Xu, A. (2015) · PubMed · Cited by 283
Cell Cycle Control of Wnt Receptor Activation
Davidson, G., Shen, J., Huang, Y.-L., Su, Y., Karaulanov, E., Bartscherer, K., Hassler, C., Stannek, P., Boutros, M., & Niehrs, C. (2009) · Developmental Cell · doi:10.1016/j.devcel.2009.11.006 · Cited by 275
MicroRNA Expression Signatures of Bladder Cancer Revealed by Deep Sequencing
Han, Y., Chen, J., Zhao, X., Liang, C., Wang, Y., Sun, L., Jiang, Z., Zhang, Z., Yang, R., Chen, J., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0018286 · Cited by 266
Desnoyers, L. R., Pai, R., Ferrando, R. E., Hötzel, K., Le, T., Ross, J., Carano, R., D'Souza, A., Qing, J., Mohtashemi, I., et al. (2008) · Oncogene · doi:10.1038/sj.onc.1210623 · Cited by 264
Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice
Qing, J., Du, X., Chen, Y., Chan, P., Li, H., Wu, P., Marsters, S., Stawicki, S., Tien, J., Totpal, K., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci38017 · Cited by 255
Turley, E. A., Veiseh, M., Radisky, D. C., & Bissell, M. J. (2008) · Nature Clinical Practice Oncology · doi:10.1038/ncponc1089 · Cited by 253
Katoh, M., & Katoh, M. (2006) · Cancer Biology & Therapy · doi:10.4161/cbt.5.9.3151 · Cited by 253
Self-citation8p11 myeloproliferative syndrome: a review
Jackson, C. C., Medeiros, L. J., & Miranda, R. N. (2010) · Human Pathology · doi:10.1016/j.humpath.2009.11.003 · Cited by 247
Minami, Y., Oishi, I., Endo, M., & Nishita, M. (2010) · Developmental Dynamics · doi:10.1002/dvdy.21991 · Cited by 240
Courjal, F., Cuny, M., Simony-Lafontaine, J., Louason, G., Speiser, P., Zeillinger, R., Rodríguez, C., & Theillet, C. G. (1997) · PubMed · Cited by 238
Hedgehog signaling, epithelial-to-mesenchymal transition and miRNA (Review)
Katoh (1998) · International Journal of Molecular Medicine · doi:10.3892/ijmm_00000019 · Cited by 234
Xu, N., Brodin, P., Wei, T., Meisgen, F., Eidsmo, L., Nagy, N., Kemeny, L., Ståhle, M., Sonkoly, E., & Pivarcsi, A. (2011) · Journal of Investigative Dermatology · doi:10.1038/jid.2011.55 · Cited by 231
Anaplastic lymphoma kinase proteins in growth control and cancer
Pulford, K., Morris, S. W., & Turturro, F. (2004) · Journal of Cellular Physiology · doi:10.1002/jcp.10472 · Cited by 227
Genetic Heterogeneity of Saethre-Chotzen Syndrome, Due to TWIST and FGFR Mutations
Paznekas, W. A., Cunningham, M. L., Howard, T. D., Korf, B. R., Lipson, M. H., Grix, A. W., Feingold, M., Goldberg, R., Borochowitz, Z., Aleck, K., et al. (1998) · The American Journal of Human Genetics · doi:10.1086/301855 · Cited by 222
Huynh, H., Ngo, V. C., Fargnoli, J., Ayers, M., Soo, K. C., Koong, H. N., Thng, C. H., Ong, H. S., Chung, A., Chow, P., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0509 · Cited by 221
Kasper, M., Schnidar, H., Neill, G. W., Hanneder, M., Klingler, S., Blaas, L., Schmid, C., Hauser-Kronberger, C., Regl, G., Philpott, M. P., et al. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.02317-05 · Cited by 220
Wnt/Planar cell polarity signaling: A new paradigm for cancer therapy
Wang, Y. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0282 · Cited by 216
March, H. N., Rust, A. G., Wright, N. A., ten Hoeve, J., de Ridder, J., Eldridge, M., van der Weyden, L., Berns, A., Gadiot, J., Uren, A., et al. (2011) · Nature Genetics · doi:10.1038/ng.990 · Cited by 189
Byron, S. A., Gartside, M., Powell, M. A., Wellens, C. L., Gao, F., Mutch, D. G., Goodfellow, P. J., & Pollock, P. M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030801 · Cited by 186
Fibroblast growth factor receptor 2 mutations in Beare–Stevenson cutis gyrata syndrome
Przylepa, K. A., Paznekas, W., Zhang, M., Golabi, M., Bias, W., Bamshad, M. J., Carey, J. C., Hall, B. D., Stevenson, R., Orlow, S. J., et al. (1996) · Nature Genetics · doi:10.1038/ng0896-492 · Cited by 185
Shimokawa, T., Furukawa, Y., Sakai, M., Li, M., Miwa, N., Lin, Y., & Nakamura, Y. (2003) · PubMed · Cited by 185
Roarty, K., & Serra, R. (2007) · Development · doi:10.1242/dev.008250 · Cited by 180
Transcriptional mechanisms of WNT5A based on NF-κB, Hedgehog, TGFβ, and Notch signaling cascades
Katoh (2009) · International Journal of Molecular Medicine · doi:10.3892/ijmm_00000190 · Cited by 174
Ripka, S., Konig, A., Buchholz, M., Wagner, M., Sipos, B., Kloppel, G., Downward, J., Gress, T., & Michl, P. (2007) · Carcinogenesis · doi:10.1093/carcin/bgl255 · Cited by 172
Common Genetic Variants and Modification of Penetrance of BRCA2-Associated Breast Cancer
Gaudet, M. M., Kirchhoff, T., Green, T., Vijai, J., Korn, J. M., Guiducci, C., Segrè, A. V., McGee, K., McGuffog, L., Kartsonaki, C., et al. (2010) · PLoS Genetics · doi:10.1371/journal.pgen.1001183 · Cited by 162
Receptor Tyrosine Kinases and Targeted Cancer Therapeutics
Takeuchi, K., & Ito, F. (2011) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.34.1774 · Cited by 159
Targeting FGFR3 in multiple myeloma: inhibition of t(4;14)-positive cells by SU5402 and PD173074
Grand, E., Chase, A., Heath, C., Rahemtulla, A., & Cross, N. (2004) · Leukemia · doi:10.1038/sj.leu.2403347 · Cited by 158
Mohammadi, M., Olsen, S. K., & Goetz, R. (2005) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2005.09.002 · Cited by 158
WNT Signaling in Stem Cell Biology and Regenerative Medicine
Katoh, M. (2008) · Current Drug Targets · doi:10.2174/138945008784911750 · Cited by 154
Self-citationTargeting EGFR and HER-2 receptor tyrosine kinases for cancer drug discovery and development
Kamath, S., & Buolamwini, J. K. (2006) · Medicinal Research Reviews · doi:10.1002/med.20070 · Cited by 152
Bello, E., Colella, G., Scarlato, V., Oliva, P., Berndt, A., Valbusa, G., Serra, S. C., D’Incalci, M., Cavalletti, E., Giavazzi, R., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2700 · Cited by 148
Holland, D. G., Burleigh, A., Git, A., Goldgraben, M. A., Pérez-Mancera, P. A., Chin, S., Hurtado, A., Bruna, A., Ali, H. R., Greenwood, W., et al. (2011) · EMBO Molecular Medicine · doi:10.1002/emmm.201100122 · Cited by 145
FGFR2-related pathogenesis and FGFR2-targeted therapeutics (Review)
Katoh (2009) · International Journal of Molecular Medicine · doi:10.3892/ijmm_00000132 · Cited by 141
Genetic Susceptibility Loci for Breast Cancer by Estrogen Receptor Status
García‐Closas, M., & Chanock, S. J. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0975 · Cited by 141
Epithelial-mesenchymal transition in gastric cancer (Review)
Katoh, M. (2005) · International Journal of Oncology · doi:10.3892/ijo.27.6.1677 · Cited by 138
Self-citationTargeting mutant fibroblast growth factor receptors in cancer
Greulich, H. E., & Pollock, P. M. (2011) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2011.01.012 · Cited by 136
The Wnt/beta-catenin pathway in adrenocortical development and cancer
El Wakil, A., & Lalli, E. (2011) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2010.11.014 · Cited by 134
Udler, M. S., Meyer, K. B., Pooley, K. A., Karlins, E., Struewing, J. P., Zhang, J., Doody, D. R., MacArthur, S., Tyrer, J. P., Pharoah, P. D. P., et al. (2009) · Human Molecular Genetics · doi:10.1093/hmg/ddp078 · Cited by 127
Functional analysis of microRNAs in human hepatocellular cancer stem cells
Meng, F., Glaser, S. S., Francis, H., DeMorrow, S., Han, Y., Passarini, J. D., Stokes, A., Cleary, J. P., Liu, X., Venter, J. K., et al. (2011) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2011.01282.x · Cited by 125
Inhibition of Fibroblast Growth Factor 19 Reduces Tumor Growth by Modulating β-Catenin Signaling
Pai, R., Dunlap, D. Y., Qing, J., Mohtashemi, I., Hötzel, K., & French, D. M. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-2325 · Cited by 125
Lee, F. S., Lane, T. F., Kuo, A. C., Shackleford, G. M., & Leder, P. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.6.2268 · Cited by 122
Loss-of-Function Fibroblast Growth Factor Receptor-2 Mutations in Melanoma
Gartside, M. G., Chen, H., Ibrahimi, O. A., Byron, S. A., Curtis, A. V., Wellens, C. L., Bengston, A., Yudt, L. M., Eliseenkova, A. V., Ma, J., et al. (2009) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-08-0021 · Cited by 121
Obesity short‐circuits stemness gene network in human adipose multipotent stem cells
Roldan, M., Macías‐González, M., García, R., Tinahones, F. J., & Martín, M. (2011) · The FASEB Journal · doi:10.1096/fj.10-171439 · Cited by 120
Bae, J. H., & Schlessinger, J. (2010) · Molecules and Cells · doi:10.1007/s10059-010-0080-5 · Cited by 118
Mitogen-Activated Protein Kinases Promote WNT/β-Catenin Signaling via Phosphorylation of LRP6
Červenka, I., Wolf, J., Mašek, J., Krejci, P., Wilcox, W. R., Kozubík, A., Schulte, G., Gutkind, J. S., & Bryja, V. (2011) · Molecular and Cellular Biology · doi:10.1128/mcb.00550-10 · Cited by 117
Tortora, G., Ciardiello, F., & Gasparini, G. (2008) · Nature Clinical Practice Oncology · doi:10.1038/ncponc1161 · Cited by 111
FGFR2 Abnormalities Underlie a Spectrum of Bone, Skin, and Cancer Pathologies
Katoh, M. (2009) · Journal of Investigative Dermatology · doi:10.1038/jid.2009.97 · Cited by 107
Self-citationWNT and FGF gene clusters (Review)
Katoh, M. (2002) · International Journal of Oncology · doi:10.3892/ijo.21.6.1269 · Cited by 102
Self-citationSaxena, R., & Dwivedi, A. (2010) · Medicinal Research Reviews · doi:10.1002/med.20209 · Cited by 101
Katoh, M. (2011) · Current Pharmaceutical Biotechnology · doi:10.2174/138920111794295710 · Cited by 99
Self-citationDeep sequencing of gastric carcinoma reveals somatic mutations relevant to personalized medicine
Holbrook, J. D., Parker, J. S., Gallagher, K. T., Halsey, W. S., Hughes, A. M., Weigman, V., Lebowitz, P. F., & Kumar, R. (2011) · Journal of Translational Medicine · doi:10.1186/1479-5876-9-119 · Cited by 97
Dimitroff, C. J., Klohs, W. D., Sharma, A., Pera, P. J., Driscoll, D. L., Veith, J. M., Steinkampf, R. W., Schroeder, M. C., Klutchko, S. R., Sumlin, A. B., et al. (1999) · Investigational New Drugs · doi:10.1023/a:1006367032156 · Cited by 96
Masola, V., Gambaro, G., Tibaldi, E. V., Brunati, A. M., Gastaldello, A., D’Angelo, A., Onisto, M., & Lupo, A. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.279836 · Cited by 96
Genetic basis of potential therapeutic strategies for craniosynostosis
Melville, H., Wang, Y., Taub, P. J., & Jabs, E. W. (2010) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.33703 · Cited by 93
Krantz, S. B., Shields, M. A., Dangi-Garimella, S. Y., Munshi, H. G., & Bentrem, D. J. (2011) · Journal of Surgical Research · doi:10.1016/j.jss.2011.09.020 · Cited by 93
Chase, A., Grand, F., & Cross, N. C. P. (2007) · Blood · doi:10.1182/blood-2007-02-074286 · Cited by 92
Frequent up-regulation of WNT5A mRNA in primary gastric cancer
Saitoh, T., Mine, T., & Katoh, M. (2002) · International Journal of Molecular Medicine · doi:10.3892/ijmm.9.5.515 · Cited by 92
Self-citationYagasaki, F., Wakao, D., Yokoyama, Y., Uchida, Y., MUROHASHI, I., Kayano, H., Taniwaki, M., Matsuda, A., & Bessho, M. (2001) · PubMed · Cited by 92
miRNAs and regulation of cell signaling
Ichimura, A., Ruike, Y., Terasawa, K., & Tsujimoto, G. (2011) · FEBS Journal · doi:10.1111/j.1742-4658.2011.08087.x · Cited by 88
Pan, B., Chan, G. K. Y., Chénard, M., Chi, A., Davis, L. J., Deshmukh, S. V., Gibbs, W. W., Gil, S., Hang, G., Hatch, H., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-2541 · Cited by 84
Wnt3a stimulation elicits G-protein-coupled receptor properties of mammalian Frizzled proteins
Koval, A., & Katanaev, V. L. (2011) · Biochemical Journal · doi:10.1042/bj20101878 · Cited by 84
Wu, W. (2011) · Oncology Reports · doi:10.3892/or.2011.1437 · Cited by 80
Huijts, P. E. A., Vreeswijk, M. P. G., Kroeze‐Jansema, K., Jacobi, C. E., Seynaeve, C., Krol-Warmerdam, E. M., Wijers‐Koster, P. M., Blom, J., Pooley, K. A., Klijn, J. G. M., et al. (2007) · Breast Cancer Research · doi:10.1186/bcr1793 · Cited by 79
Evolutionary history of the Snail/Scratch superfamily
Barrallo‐Gimeno, A., & Nieto, M. A. (2009) · Trends in Genetics · doi:10.1016/j.tig.2009.04.001 · Cited by 77
Squarzoni, P., Parveen, F., Zanetti, L. C. D. S., Ristoratore, F., & Spagnuolo, A. (2011) · Development · doi:10.1242/dev.057323 · Cited by 74
Konecny, G. E., Kolarova, T. R., O’Brien, N. A., Winterhoff, B. J. N., Yang, G., Qi, J., Qi, Z., Venkatesan, N., Ayala, R., Luo, T., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0999 · Cited by 74
Zhao, W.-M., Wang, L., Park, H., Chhim, S., Tanphanich, M., Yashiro, M., & Kim, K. J. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0531 · Cited by 73
Nakamura, K., Yashiro, M., Matsuoka, T., Tendo, M., Shimizu, T., Miwa, A., & Hirakawa, K. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.08.030 · Cited by 70
Zhao, Q., Kirkness, E. F., Caballero, O. L., Galante, P. A. F., Parmigiani, R. B., Edsall, L., Kuan, S., Ye, Z., Levy, S., de Vasconcelos, A. T. R., et al. (2010) · Genome biology · doi:10.1186/gb-2010-11-11-r114 · Cited by 62
FGF Receptor Inhibitors: Role in Cancer Therapy
Daniele, G., Corral, J., Molife, L. R., & Bono, J. S. D. (2012) · Current Oncology Reports · doi:10.1007/s11912-012-0225-0 · Cited by 59
Advances in MicroRNAs: Implications for Gene Therapists
Marquez, R. T., & McCaffrey, A. P. (2007) · Human Gene Therapy · doi:10.1089/hum.2007.147 · Cited by 56
FOXO1–FGFR1 fusion and amplification in a solid variant of alveolar rhabdomyosarcoma
Liu, J.-L., Guzmán, M. A., Pezanowski, D. M., Patel, D. M., Hauptman, J. E., Keisling, M., Hou, S. J., Papenhausen, P., Pascasio, J., Punnett, H., et al. (2011) · Modern Pathology · doi:10.1038/modpathol.2011.98 · Cited by 56
Targeting fibroblast-growth-factor-receptor-dependent signaling for cancer therapy
Heinzle, C. F., Sutterlüty, H., Grusch, M., Grasl‐Kraupp, B., Berger, W., & Marian, B. (2011) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2011.566217 · Cited by 55
Role of Epigenomics in Ovarian and Endometrial Cancers
Balch, C., Matei, D. E., Huang, T. H. ‐., & Nephew, K. P. (2010) · Epigenomics · doi:10.2217/epi.10.19 · Cited by 55
Synergistic antitumor effects of FGFR2 inhibitor with 5‐fluorouracil on scirrhous gastric carcinoma
Yashiro, M., Shinto, O., Nakamura, K., Tendo, M., Matsuoka, T., Matsuzaki, T., Kaizaki, R., Miwa, A., & Hirakawa, K. (2009) · International Journal of Cancer · doi:10.1002/ijc.24763 · Cited by 53
Pond, A. C., Herschkowitz, J. I., Schwertfeger, K. L., Welm, B. E., Zhang, Y., York, B., Cardiff, R. D., Hilsenbeck, S. G., Perou, C. M., Creighton, C. J., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4404 · Cited by 53
Canning, C. A., Lee, L., Luo, S. X., Graham, A., & Jones, C. M. (2008) · Neural Development · doi:10.1186/1749-8104-3-35 · Cited by 52
Development of RET Kinase Inhibitors for Targeted Cancer Therapy
Mologni, L. (2011) · Current Medicinal Chemistry · doi:10.2174/092986711794088308 · Cited by 51
Lin, N., Chen, S., Pan, W., Xu, L., Hu, K., & Xu, R. (2011) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00452.2010 · Cited by 51
Matsuda, Y., Ishiwata, T., Yamahatsu, K., Kawahara, K., Hagio, M., Peng, W., Yamamoto, T., Nakazawa, N., Seya, T., Ohaki, Y., et al. (2011) · Cancer Letters · doi:10.1016/j.canlet.2011.06.009 · Cited by 50
Cunningham, D. L., Sweet, S. M. M., Cooper, H. J., & Heath, J. K. (2010) · Journal of Proteome Research · doi:10.1021/pr9010475 · Cited by 49
Wnt5a as an Effector of TGFβ in Mammary Development and Cancer
Serra, R. A., Easter, S. L., Jiang, W. G., & Baxley, S. E. (2011) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1007/s10911-011-9205-5 · Cited by 49
A FGFR2 inhibitor, Ki23057, enhances the chemosensitivity of drug-resistant gastric cancer cells
Qiu, H., Yashiro, M., Zhang, X., et al. (2011) · Cancer Letters · doi:10.1016/j.canlet.2011.03.015 · Cited by 47
Lallemand, B., Chaix, F., Bury, M., Bruyère, C., Ghostin, J., Becker, J., Delporte, C., Gelbcke, M., Mathieu, V., Dubois, J., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200285z · Cited by 44
Katoh, M. (2010) · Expert Review of Anticancer Therapy · doi:10.1586/era.10.128 · Cited by 44
Self-citationHuijts, P. E. A., van Dongen, M., de Goeij, M. C. M., van Moolenbroek, A. J., Blanken, F., Vreeswijk, M. P. G., de Kruijf, E. M., Mesker, W. E., van Zwet, E. W., Tollenaar, R. A. �. �., et al. (2011) · Breast Cancer Research · doi:10.1186/bcr2917 · Cited by 38
Anti-VEGF and beyond: shaping a new generation of anti-angiogenic therapies for cancer
Bertolini, F., Marighetti, P., Martín-Padura, I., Mancuso, P., Hu‐Lowe, D. D., Shaked, Y., & d’Onofrio, A. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2011.08.007 · Cited by 38
FGFR2 genotype and risk of radiation-associated breast cancer in Hodgkin lymphoma
Ma, Y. P., van Leeuwen, F. E., Cooke, R., Broeks, A., Enciso-Mora, V., Olver, B. D., Lloyd, A., Broderick, P., Russell, N. S., Janus, C. P. M., et al. (2011) · Blood · doi:10.1182/blood-2011-10-383380 · Cited by 36
Belleudi, F., Scrofani, C., Torrisi, M. R., & Mancini, P. (2011) · PLoS ONE · doi:10.1371/journal.pone.0029159 · Cited by 35
Physiological inhibitors of Wnt signaling
Filipovich, A., Gehrke, I., Poll‐Wolbeck, S. J., & Kreuzer, K. (2011) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2011.01592.x · Cited by 34
FGF-1 and FGF-2 modulate the E-cadherin/catenin system in pancreatic adenocarcinoma cell lines
EL‐HARIRY, I., Pignatelli, M. N., & Lemoine, N. R. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.1813 · Cited by 34
Differentiation pathways in carcinogenesis and in chemo- and radioresistance
Janíková, M., & Škarda, J. (2011) · Neoplasma · doi:10.4149/neo_2012_002 · Cited by 29
Ota, S., Zhou, Z.-Q., Link, J. M., & Hurlin, P. J. (2009) · Human Molecular Genetics · doi:10.1093/hmg/ddp195 · Cited by 27
Pavlovich, A. L., Boghaert, E., & Nelson, C. M. (2011) · Experimental Cell Research · doi:10.1016/j.yexcr.2011.03.017 · Cited by 26
Protein partners in the life history of activated fibroblast growth factor receptors
Vecchione, A., Cooper, H. J., Trim, K. J., Akbarzadeh, S., Heath, J. K., & Wheldon, L. M. (2007) · PROTEOMICS · doi:10.1002/pmic.200700615 · Cited by 23
Epigenetic Regulation Of Wnt Signaling In Chronic Lymphocytic Leukemia
Bennett, L. B., Taylor, K. H., Arthur, G. L., Rahmatpanah, F. B., Hooshmand, S., & Caldwell, C. W. (2010) · Epigenomics · doi:10.2217/epi.09.43 · Cited by 22
Translational applications of microRNA genes in medulloblastomas
Ajeawung, N. F., Li, B., & Kamnasaran, D. (2010) · Clinical and investigative medicine · doi:10.25011/cim.v33i4.14225 · Cited by 9
Cited by
The Fibroblast Growth Factor signaling pathway
Ornitz, D. M., & Itoh, N. (2015) · WIREs Developmental Biology · doi:10.1002/wdev.176 · Cited by 2,050
Angiogenic signaling pathways and anti-angiogenic therapy for cancer
Liu, Z.-L., Chen, H.-H., Zheng, L.-L., Sun, L.-P., & Shi, L. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01460-1 · Cited by 1,300
Kinase-targeted cancer therapies: progress, challenges and future directions
Bhullar, K. S., Lagarón, N. O., McGowan, E. M., Parmar, I., Jha, A., Hubbard, B. P., & Rupasinghe, H. P. V. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0804-2 · Cited by 1,245
Targeting the tumour stroma to improve cancer therapy
Valkenburg, K. C., de Groot, A. E., & Pienta, K. J. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0007-1 · Cited by 1,084
The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing
Helsten, T., Elkin, S., Arthur, E., Tomson, B. N., Carter, J., & Kurzrock, R. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3212 · Cited by 808
Metadata
- Authors
- Katoh, M., & Nakagama, H.
- Venue
- Medicinal Research Reviews
- Publisher
- Wiley
- Published
- 2013-05-21
- Volume
- 34
- Issue
- 2
- Pages
- 280-300
- ISSN
- 0198-6325 (ISSN-L)
- OpenAlex
- W1894751757
- Cited by
- 610
- References
- 157
- FWCI
- 17.62
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.